Welcome to our dedicated page for Amicus Therapeutics news (Ticker: $FOLD), a resource for investors and traders seeking the latest updates and insights on Amicus Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amicus Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amicus Therapeutics's position in the market.
Amicus Therapeutics reported a total revenue of $110.4M for 1Q 2024, showing a 28% increase year-over-year. They raised their full-year 2024 revenue growth guidance to 25%-30%. Galafold sales increased by 15%, with Pombiliti + Opfolda sales growing by 30%. Non-GAAP profitability is projected for 2024. The company aims to achieve double-digit Galafold revenue growth and launch Pombiliti + Opfolda successfully.
Amicus Therapeutics will participate in the Bank of America 2024 Health Care Conference in Las Vegas. The company aims to present its dedication to developing medicines for rare diseases. The event will feature a fireside chat with management on May 15, 2024, at 1:40 p.m. P.T.
Amicus Therapeutics (Nasdaq: FOLD) will announce its first-quarter 2024 financial results on May 9, 2024. A conference call and live webcast will be held to discuss the results. The company is a global biotechnology firm focused on developing medicines for rare diseases.